Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl(Cardiovascular Center Bethanien), Joyce O’Shaughnessy(Baylor University Medical Center), Michael Untch(Helios Hospital Berlin-Buch), William M. Sikov(Providence College), Hope S. Rugo(University of California, San Francisco), Mark D. McKee(AbbVie (United States)), Jens Huober(Universität Ulm), Mehra Golshan(Brigham and Women's Hospital), Gϋnter von Minckwitz(German Breast group), David Maag(AbbVie (United States)), Danielle Sullivan(AbbVie (United States)), Norman Wolmark(NSABP Foundation), Kristi McIntyre(Texas Oncology), José Ponce(GEICAM – Spanish Breast Cancer Group), Otto Metzger(Harvard University), Priya Rastogi(Magee-Womens Hospital), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Xuan Liu(AbbVie (United States)), Charles E. Geyer(Virginia Commonwealth University)
Cited by 767
Abstract
Related Papers
No related papers found
Powered by citation graph analysis